| 前收盘价格 | 0.120 |
| 收盘价格 | 0.120 |
| 成交量 | 50,843 |
| 平均成交量 (3个月) | 172,637 |
| 市值 | 125,301,192 |
| 价格/销量 (P/S) | 106.02 |
| 股市价格/股市净资产 (P/B) | 16.25 |
| 52周波幅 | |
| 利润日期 | 26 Aug 2025 - 1 Sep 2025 |
| 营业毛利率 | -100.32% |
| 营业利益率 (TTM) | -91.93% |
| 稀释每股收益 (EPS TTM) | -0.010 |
| 季度收入增长率 (YOY) | 245.70% |
| 总债务/股东权益 (D/E MRQ) | 1.74% |
| 流动比率 (MRQ) | 9.19 |
| 营业现金流 (OCF TTM) | -5.86 M |
| 杠杆自由现金流 (LFCF TTM) | -4.54 M |
| 资产报酬率 (ROA TTM) | -21.87% |
| 股东权益报酬率 (ROE TTM) | -35.59% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Scientific & Technical Instruments (AU) | 混合的 | 混合的 |
| Scientific & Technical Instruments (全球的) | 混合的 | 混合的 | |
| 股票 | OPTISCAN FPO [OIL] | - | - |
AIStockmoo 评分
0.4
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 1.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.38 |
|
Optiscan Imaging Ltd is engaged in the development, manufacture, and commercialization of endomicroscopic digital imaging technology solutions for medical, translational, and pre-clinical applications. Its technology offers real-time, 3D, in vivo imaging at the single-cell level, in a non-destructive manner that enables clinicians to make immediate informed decisions. Its products include InVivage, ViewnVivo, and Customisation. Its geographical segments include Australia, Germany, Norway, China, and the United States. |
|
| 部门 | Technology |
| 行业 | Scientific & Technical Instruments |
| 投资方式 | Small Core |
| 内部持股比例 | 43.40% |
| 机构持股比例 | 18.57% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合